Since auranofin also showed beneficial effects in liver disease models and inhibited hepatic steatosis and fibrosis in NAFLD (non-alcoholic fatty liver disease) by suppression of NF-κB activity, it might also ameliorate the liver-damaging effects of the approved antifungals flucytosine and amphotericin B [162,163]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.